Valoe Oyj
Valoe Corporation Stock Exchange Release 21 January 2021 at 10.00 Finnish time
The Board of Directors of Valoe Corporation (the "Company") has, pursuant to the terms and conditions of the financing arrangement between Valoe Corporation and Winance announced on 22 April 2020, resolved to approve the request of Winance to convert a proportion of EUR 74,000 of the convertible notes to the shares in the Company at conversion price of EUR 0.05 per share. The conversion shall be executed by transferring a total of 1,480,000 treasury shares to Winance. After the transfer, the Company will have in total 12,285,616 treasury shares.
In Mikkeli 21 January 2021
Valoe Corporation
Board of Directors
For more information:
Iikka Savisalo, President and CEO, Valoe Corporation
Tel. +358 40 521 6082
email: iikka.savisalo@valoe.com
Distribution:
NASDAQ OMX, Helsinki
Main media
www.valoe.com
Valoe Corporation specializes in the clean energy, especially in photovoltaic solutions. Valoe provides automated production technology for solar modules based on the company’s own technology; production lines for modules; solar modules and special components for solar modules. Valoe's head office is located in Mikkeli, Finland.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Wolters Kluwer N.V.19.9.2025 08:00:00 CEST | Press release
Wolters Kluwer completes capital reduction
Orion Oyj19.9.2025 08:00:00 CEST | Press release
80,802 Orion Corporation A shares converted into B shares
JDE Peet's N.V.19.9.2025 07:55:00 CEST | Press release
Update on intended recommended public offer by KDP for JDE Peet's
Sampo plc19.9.2025 07:30:00 CEST | Press release
Sampo plc’s share buybacks 18 September 2025
Idorsia Pharmaceuticals Ltd19.9.2025 07:00:00 CEST | Press release
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom